This finding strongly suggests that characterisation of the transcriptome signature regulated by SRPK1 in other tumour types could provide valuable insights regarding its oncogenic activity, as well as suggestions about potential targets to be tested in combined therapeutic approaches. Here, SRPK1 is linked to neoplasm.